The gatekeeper of reproductive hormones
Injection · 503A Compounding
Educational content. This page describes Kisspeptin-10 for informational purposes only and is not medical advice, diagnosis, or treatment. Consult a licensed provider before starting, stopping, or modifying any therapy.
Researched and maintained by the PepHookup team. Regulatory status last verified April 12, 2026.
As an oocyte-maturation trigger, kisspeptin recruits the patient's own GnRH to produce a self-limiting LH surge lasting roughly 12 to 14 hours. In a phase 2 trial of 60 women at high risk of ovarian hyperstimulation syndrome, oocyte maturation occurred in 95 percent of patients with no case of moderate, severe, or critical OHSS at any dose.[12][13]
A single intravenous bolus of kisspeptin-10 evokes a discrete pulse of GnRH release and shifts the timing of the hypothalamic GnRH clock, delaying the next endogenous pulse. This confirms that kisspeptin acts upstream as a master timekeeper of the reproductive axis.[7]
In a proof-of-concept study, an 11-hour intravenous infusion of kisspeptin-10 raised testosterone from 8.5 to 11.4 nmol/L and increased LH pulse frequency in hypotestosteronemic men with type 2 diabetes, showing that kisspeptin can engage a metabolically suppressed reproductive axis.[5][8]
Kisspeptin-10 (KP-10) is the shortest biologically active fragment of the kisspeptins, a family of peptides cleaved from the precursor encoded by the KISS1 gene on chromosome 1q32. KISS1 was first described in 1996 as a metastasis-suppressor gene in human malignant melanoma, and the name traces to Hershey, Pennsylvania (home of Hershey's Kisses) combined with the suppressor-sequence designation. Its central role in reproduction emerged in 2003, when two groups independently showed that loss-of-function mutations in its receptor, KISS1R (then called GPR54), cause hypogonadotropic hypogonadism and absent puberty.
Kisspeptin-10 carries the amino acid sequence Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2. Every kisspeptin variant, including the 54-, 14-, 13-, and 10-residue forms, shares this C-terminal decapeptide ending in an Arg-Phe-amide motif, and all bind KISS1R with comparable affinity. The C-terminal amidation is essential for activity. KP-10 is cleared rapidly with a circulating half-life of only a few minutes, whereas the longer kisspeptin-54 persists for roughly half an hour, which is why most reproductive trials have used the longer form.
Kisspeptin binds KISS1R, a Gq/G11-coupled receptor expressed on the large majority of GnRH neurons in the hypothalamus. Receptor activation engages phospholipase C, which generates IP3 and diacylglycerol, mobilizing intracellular calcium and activating protein kinase C. In recordings from GnRH neurons, kisspeptin produces a sustained depolarization driven by opening of TRPC-like cation channels alongside reduced potassium conductance.
That depolarization makes GnRH neurons fire and release GnRH into the hypophysial portal vasculature, where it reaches the anterior pituitary and stimulates luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from gonadotropes. These gonadotropins then drive gonadal sex-steroid production and gametogenesis. Because the signal works through the patient's own pituitary reserve, the gonadotropin response is bounded by physiology rather than forced by an exogenous receptor agonist.
In the arcuate nucleus, kisspeptin neurons co-express neurokinin B and dynorphin, forming the KNDy network that behaves as the GnRH pulse generator. A separate kisspeptin population in the anteroventral periventricular region mediates estrogen positive feedback and helps drive the preovulatory LH surge in females. The response is sexually dimorphic. Intravenous kisspeptin-10 reliably raises gonadotropins in men, but in women it stimulates LH and FSH during the preovulatory phase while having little effect during the early follicular phase.
The gatekeeper of reproductive hormones
Kisspeptin-10 activates KISS1R on hypothalamic GnRH neurons through Gq/G11 signaling, opening TRPC-like cation channels and depolarizing the neuron to release GnRH. GnRH then stimulates pituitary LH and FSH secretion. The arcuate KNDy network (kisspeptin, neurokinin B, dynorphin) shapes the pulsatile GnRH pattern that underlies normal reproductive function.
A 90-minute intravenous infusion of kisspeptin-54 markedly increased serum LH, with a smaller rise in FSH and a subsequent increase in testosterone, establishing that kisspeptin stimulates the human hypothalamic-pituitary-gonadal axis. This study also characterized the kisspeptin-54 half-life of roughly 28 minutes.
Dhillo WS, Chaudhri OB, Patterson M, et al. · J Clin Endocrinol Metab, 90(12):6609-6615 (2005) · PubMed
An intravenous bolus of kisspeptin-10 produced a dose-dependent LH rise that peaked at 1 mcg/kg (4.1 to 12.4 IU/L), while 3 mcg/kg gave a smaller response, indicating desensitization at high doses. A lower-dose infusion increased LH pulse frequency from 0.7 to 1.0 pulses per hour and raised secretory burst mass.
George JT, Veldhuis JD, Roseweir AK, et al. · J Clin Endocrinol Metab, 96(8):E1228-E1236 (2011) · PubMed
Oocyte maturation occurred in 95 percent of women. Across all doses, biochemical pregnancy, clinical pregnancy, and live-birth rates per transfer were 63, 53, and 45 percent. No woman developed moderate, severe, or critical OHSS at any dose tested.
Abbara A, Jayasena CN, Christopoulos G, et al. · J Clin Endocrinol Metab, 100(9):3322-3331 (2015) · PubMed
A second 9.6 nmol/kg dose at 10 hours raised the proportion of women reaching an oocyte yield of 60 percent or more from 45 percent (14/31) to 71 percent (21/31), p = 0.042, without increasing ovarian over-response. No woman in the dual-dose group developed moderate OHSS.
Abbara A, Clarke S, Islam R, et al. · Hum Reprod, 32(9):1915-1924 (2017) · PubMed
An 11-hour intravenous infusion of kisspeptin-10 increased LH from 3.9 to 20.7 IU/L (p = 0.03) and testosterone from 8.5 to 11.4 nmol/L (p = 0.002), with LH pulse frequency rising from 0.6 to 0.9 pulses per hour, suggesting kisspeptin can stimulate the reproductive axis despite metabolic suppression.
George JT, Veldhuis JD, Tena-Sempere M, et al. · Clin Endocrinol (Oxf), 79(1):100-104 (2013) · PubMed
start low, go slow
IV bolus (kisspeptin-10, research)
IV infusion (kisspeptin-10, research)
Subcutaneous injection (kisspeptin-54, IVF trigger)
IV bolus (kisspeptin-10, research): Half-life of only a few minutes. Doses near 3 mcg/kg produced a smaller response than 1 mcg/kg, consistent with rapid receptor desensitization.
IV infusion (kisspeptin-10, research): Used to study LH pulse dynamics and in the type 2 diabetes testosterone-recovery study, where a 4 mcg/kg/hour infusion ran for 11 hours.
Subcutaneous injection (kisspeptin-54, IVF trigger): Produces a self-limiting LH surge lasting roughly 12 to 14 hours. The longer-acting analog MVT-602 has been studied to extend this surge.
All published kisspeptin protocols have been carried out in controlled research or IVF settings under specialist supervision, and any dose, route, and schedule would be determined by a licensed provider. Kisspeptin-10 is investigational and not approved for any clinical indication.
Kisspeptin-10 is cleared within minutes, while kisspeptin-54 lasts roughly 28 minutes, which is why reproductive trials favor KP-54 and why a longer-acting analog (MVT-602) has been developed to extend the LH surge.
Continuous or twice-daily dosing for more than about two weeks can cause tachyphylaxis as KISS1R is internalized, blunting the gonadotropin response. Intermittent dosing preserves responsiveness, and the underlying GnRH neurons stay functional during tachyphylaxis.
No serious adverse events have been reported in published kisspeptin clinical trials. Heart rate, blood pressure, electrolytes, and liver and renal parameters remained normal across studies.
The most consequential clinical finding is the near-absence of ovarian hyperstimulation syndrome when kisspeptin is used as an IVF trigger. Across the OHSS-prevention trials, no woman developed moderate, severe, or critical OHSS at any tested dose.
Because kisspeptin acts upstream at the hypothalamus, the response depends on the patient's own GnRH and pituitary reserve. That gives a built-in ceiling, since the effect is bounded by physiology rather than driven by a supraphysiologic agonist acting directly on the ovary.
Human exposure to date is limited to short research and IVF protocols. Long-term safety data and data on repeated or chronic use do not exist, and kisspeptin is not FDA-approved as a drug.
| Peptide | Primary Use | Administration | Cycle Length | Key Differentiator |
|---|---|---|---|---|
| Kisspeptin-10 | Reproductive Hormone Regulation | IV or Subcutaneous Injection | Single dose or short-term protocol | Acts at the top of the reproductive cascade in the hypothalamus to produce a physiologic, self-limiting LH surge with near-zero OHSS risk, unlike hCG, which acts directly on ovarian LH receptors. |
| Tesamorelin | Visceral Fat & GHRH Signaling | Subcutaneous Injection | Ongoing daily | The only FDA-approved GHRH analog, with Phase III data in over 800 patients, documented liver-fat reduction, and physiologic pulsatile GH release |
| Sermorelin | GH restoration and healthy aging | Subcutaneous injection, daily at bedtime | 3-6 months | The GHRH analog with prior FDA approval and a multi-decade clinical record, preserving natural feedback rather than replacing growth hormone |
| Ibutamoren (MK-677) | Anti-Aging & Body Composition | Oral | 8 to 16 weeks typical | The only well-studied orally active ghrelin-receptor agonist, delivering sustained 24-hour IGF-1 elevation without injections, unlike peptide secretagogues such as CJC-1295 or ipamorelin. |
| IGF-1 LR3 | Muscle growth and recovery (claimed; preclinical only) | Injection | 4 to 7 days (animal studies only) | Sharply reduced IGFBP binding keeps the peptide free and active far longer than native IGF-1, extending bioavailability but also removing the natural brake on IGF-1 signaling |
The FDA placed this substance in Category 2 of the 503A bulk drug substances evaluation, flagging significant safety risks. 503A compounding carries FDA enforcement risk, so most pharmacies decline to prepare it and many physicians hesitate to prescribe it.
Listed in Category 2. Kisspeptin-10 is a key regulator of the hypothalamic-pituitary-gonadal axis, studied for ovulation induction, IVF protocols, and hypogonadism diagnosis. FDA cited immunogenicity concerns and limited human safety data for compounding routes. Not eligible for compounding under the interim policy. Not among the 12 peptides HHS withdrew from Category 2 in April 2026.
Listed as 'Kisspeptin-10' in 503A Category 2
Last verified April 12, 2026. PepHookup tracks public FDA actions. This is not legal or medical advice.
George JT, Veldhuis JD, Tena-Sempere M, et al. “Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadism.” Clin Endocrinol (Oxf), 79(1):100-104 (2013)
Looking into Kisspeptin-10? Find a provider who knows this peptide and can walk you through your options.
Find a ProviderA stabilized 44-residue GHRH analog that stimulates endogenous growth hormone secretion.
FDA-approved as Egrifta for HIV-associated lipodystrophy; strongest clinical evidence of the GHRH analog family.
A 29-residue GHRH analog that prompts the pituitary to release endogenous growth hormone.
Formerly marketed as Geref for pediatric GH deficiency; discontinued in 2008 for commercial reasons.
An orally active ghrelin receptor agonist that elevates growth hormone and IGF-1.
A non-peptide small molecule marketed alongside peptides; named in the April 2026 HHS Category 2 withdrawal for PCAC re-evaluation.
“Advanced peptide therapies and personalized luxury care for optimal health, vitality, and longevity.”
Vetted providers offering Kisspeptin-10.